6-hydrazinopyridine-3-carboxylic-acid and Triple-Negative-Breast-Neoplasms

Triple-negative breast cancer (TNBC) is more prone to distant metastasis and visceral recurrence in comparison to other breast cancer subtypes, and is related to dismal prognosis. Nevertheless, TNBC has an undesirable response to targeted therapies. Therefore, to tackle the huge challenges in the diagnosis and treatment of TNBC, Nectin-4 was selected as a theranostic target because it was recently found to be highly expressed in TNBC. We developed anti-Nectin-4 monoclonal antibody (mAb. Nectin-4 expression levels of breast cancer cells (MDA-MB-468: TNBC cells; and MCF-7, non-TNBC cells) were proved by western blot, flow cytometry, and immunofluorescence imagning. Cell uptake assays, SPECT imaging, and biodistribution were performed to evaluate Nectin-4 targeting of. Nectin-4 is overexpressed in MDA-MB-468 TNBC cells, which could specifically uptake. mAb

Topics: Antibodies, Monoclonal; Cell Line, Tumor; Humans; Hydrazines; Immunoconjugates; Indocyanine Green; Nectins; Nicotinic Acids; Photothermal Therapy; Single Photon Emission Computed Tomography Computed Tomography; Tissue Distribution; Triple Negative Breast Neoplasms